Compare LUMN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LUMN | ABVX |
|---|---|---|
| Founded | 1968 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.7B |
| IPO Year | 1994 | N/A |
| Metric | LUMN | ABVX |
|---|---|---|
| Price | $6.79 | $123.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $7.25 | ★ $130.85 |
| AVG Volume (30 Days) | ★ 9.4M | 763.1K |
| Earning Date | 04-30-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,402,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.01 | $4.77 |
| 52 Week High | $11.95 | $148.83 |
| Indicator | LUMN | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 53.78 |
| Support Level | $6.28 | $106.37 |
| Resistance Level | $7.39 | $131.27 |
| Average True Range (ATR) | 0.32 | 5.01 |
| MACD | 0.04 | 1.08 |
| Stochastic Oscillator | 52.25 | 80.07 |
Lumen Technologies is one of the largest telecommunications carriers serving global enterprises. The merger with Level 3 in 2017, the 2022 divestiture of much of its local phone business in rural areas, and the 2026 sale of its remaining consumer fiber network to AT&T have shifted the company's operations away from the legacy consumer business and toward enterprises services, which account for about 90% of revenue. Lumen offers businesses a full suite of communications services, providing colocation and data center services, data transportation, phone service, and internet access.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.